EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
/PRNewswire/ -- EIP Pharma Inc. ("EIP Pharma" or the "Company"), a privately held clinical-stage company focused on developing treatments for neurodegenerative...